These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 20163839

  • 1. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
    Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T.
    Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
    [Abstract] [Full Text] [Related]

  • 2. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 May; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 3. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 4. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
    Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    Urology; 2007 Mar; 69(3):500-4. PubMed ID: 17382153
    [Abstract] [Full Text] [Related]

  • 6. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
    Deng JH, Yang LP, Wang LS, Zhou DF.
    Asian J Androl; 2004 Mar; 6(1):75-7. PubMed ID: 15064839
    [Abstract] [Full Text] [Related]

  • 7. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.
    Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
    [Abstract] [Full Text] [Related]

  • 8. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
    Deng J, Li W, Yang L, Wang L, Zou D.
    Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
    [Abstract] [Full Text] [Related]

  • 9. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [Abstract] [Full Text] [Related]

  • 10. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S.
    Cancer; 2009 Aug 01; 115(15):3468-74. PubMed ID: 19484786
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM, Ma JZ, Basler JW, Welch MD.
    Urology; 2006 Jan 01; 67(1):152-5. PubMed ID: 16413352
    [Abstract] [Full Text] [Related]

  • 12. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 13. The relationship between daily calcium intake and bone mineral density in men with prostate cancer.
    Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX.
    BJU Int; 2007 Apr 01; 99(4):812-5; discussion 815-6. PubMed ID: 17378843
    [Abstract] [Full Text] [Related]

  • 14. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
    Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL.
    Cancer; 2002 Nov 15; 95(10):2136-44. PubMed ID: 12412167
    [Abstract] [Full Text] [Related]

  • 15. Low bone mineral density in hormone-naïve men with prostate carcinoma.
    Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS.
    Cancer; 2001 Jun 15; 91(12):2238-45. PubMed ID: 11413511
    [Abstract] [Full Text] [Related]

  • 16. Editorial comment.
    Shepard DR.
    Urology; 2010 May 15; 75(5):1137. PubMed ID: 20451735
    [No Abstract] [Full Text] [Related]

  • 17. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
    Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y, Kadono Y, Takashima M, Koh E, Namiki M.
    Urology; 2009 Jun 15; 73(6):1342-6. PubMed ID: 19371939
    [Abstract] [Full Text] [Related]

  • 18. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.
    J Urol; 2006 Sep 15; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [Abstract] [Full Text] [Related]

  • 19. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    J Urol; 2006 May 15; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [Abstract] [Full Text] [Related]

  • 20. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
    Isahaya E, Hara N, Nishiyama T, Hoshii T, Takizawa I, Takahashi K.
    Prostate; 2010 Feb 01; 70(2):155-61. PubMed ID: 19760629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.